Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C, Hsu J, Kim Y, Hu D-Q, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, et al.
Arthritis Res Ther. 2013; 15(5):R146. Epub 2013 Oct 04. PMID: 24286216.Abstract